Vaccine critics head to Capitol Hill
With Lauren Gardner
Driving The Day
TAKING THE ANTI-VAX TEMPERATURE — A Senate investigations panel hearing today could help gauge how the anti-vaccine movement — and members of Congress — feel about HHS Secretary Robert F. Kennedy Jr.'s moves on vaccines so far.
The Homeland Security and Governmental Affairs subcommittee hearing on how 'health officials downplayed and hid myocarditis and other adverse events' associated with Covid-19 vaccines comes a day after federal health officials released a new framework for vaccines. The FDA also said it would limit approvals of future Covid vaccines to adults 65 and older or people with an underlying condition, a marked change from the broad-based recommendations of the past several years.
Why it matters: Amid a growing distrust of vaccines and the medical community, there's also been a growing divide in the Make America Healthy Again initiative: those who are pleased with how Kennedy — who leads the movement to combat chronic diseases — has moved to reevaluate vaccines versus those who want him to go further.
In recent weeks, wellness influencer Dr. Casey Means has faced conservative backlash after she was nominated to be U.S. surgeon general, partly for not being anti-vaccine enough, The Washington Post reported.
Since his confirmation, Kennedy has falsely claimed MMR vaccines contain aborted fetus debris, given noncommittal statements on measles prevention before promoting vaccination and said vaccines aren't safety tested enough.
However, as he promised before becoming secretary, he's stopped short of outright calling for certain vaccines to be pulled from the market.
The witnesses at today's hearing represent a more extreme contingency of vaccine skeptics, and their testimony could show how they feel about Kennedy's restraint. They include:
— Aaron Siri, a vaccine injury lawyer and close ally of Kennedy's. Siri has challenged Covid vaccine mandates and petitioned the FDA to rescind the approval of polio vaccines. He was Kennedy's personal attorney.
— Cardiologist Peter McCollough, who's been accused of spreading Covid vaccine misinformation and falsely linking the vaccine to deaths by misrepresenting federal data. McCollough is also chief scientific officer of a supplement and telehealth company whose CEO recently filed an ethics complaint against Kennedy adviser Calley Means.
— Obstetrician James Thorp, who, with McCollough, has urged a moratorium on Covid vaccines in pregnancy, falsely claiming they lead to increased risk of miscarriage. The new FDA plan lists pregnancy as an underlying condition.
— Orthopedic surgeon Joel Wallskog, who founded a vaccine injury advocacy group after he said he received a spinal cord injury following a Covid shot.
Also testifying is Dr. Jordan Vaughn, who treats long Covid and vaccine injuries, and Democratic Hawaii Governor Josh Green, a doctor who was critical of Kennedy's confirmation due to his anti-vaccine advocacy.
Key context: The FDA added a warning to Covid vaccine fact sheets in 2021 about myocarditis, or inflammation of the heart muscle, after a CDC safety panel determined a 'likely association' between the mRNA shots and the condition. The CDC says cases are rare but are most likely to be observed in young males.
WELCOME TO WEDNESDAY PULSE. Former President Joe Biden's diagnosis of advanced prostate cancer has ignited conversation about how his cancer was caught so late. Some experts say it could be because of recommendations against screening for men over 70. Send your tips, scoops and feedback to ccirruzzo@politico.com and khooper@politico.com and follow along @ChelseaCirruzzo and @Kelhoops.
In Congress
BIG BEAUTIFUL BILL CBO SCORE — More than 8.6 million more people could lose their health insurance if a draft portion of the House GOP's party-line megabill is implemented, according to an estimate from the nonpartisan Congressional Budget Office released Tuesday, POLITICO's Ben Leonard and Robert King report.
While the bill would lead to nearly $800 billion in savings over 10 years — 7.6 million people would lose Medicaid benefits and 1 million would lose plans purchased through the Affordable Care Act marketplace.
Among that group, 1.4 million people would lose health coverage from provisions under consideration for inclusion in the bill that would bar federal payments in Medicaid for people whose immigration status hasn't been verified.
Why it matters: The latest projections from the congressional scorekeeper come at a delicate moment in the negotiations around the final text of President Donald Trump's 'big, beautiful bill' of tax cuts and extensions, border security investments, energy policies and more.
Republicans across the conference are increasingly wary about the political blowback of cuts to Medicaid specifically, with Trump telling members in a closed-door GOP conference meeting early Tuesday not to 'fuck around with Medicaid.'
RUBIO DEFENDS FOREIGN AID CUTS — Secretary of State Marco Rubio pushed back on Democratic senators' claims Tuesday that global health and food-assistance cuts have killed hundreds of thousands of children in the world's poorest countries, POLITICO's Carmen Paun reports.
In his first appearance before lawmakers since billionaire Elon Musk's Department of Government Efficiency dismantled the U.S. Agency for International Development, Rubio took responsibility for those decisions and said he reviewed line by line the contracts and grants that were canceled and those that were retained.
Appearing before two Senate committees Tuesday to defend a halving of the State Department's budget for the 2026 fiscal year, as proposed by the White House, Rubio gave few explanations for the freeze and cancellation of global health grants and contracts over the last four months.
The secretary didn't explain why the State Department planned to cut all funding to Gavi, the Vaccine Alliance, which helps low-income countries buy and deliver vaccines. But he insisted that 'we are still doing vaccines,' mentioning vaccines for malaria.
He also said that 85 percent of the grants and contracts under the President's Emergency Plan for AIDS Relief, or PEPFAR, were operational.
What's next: Rubio will face two House committees today — Foreign Affairs and the Appropriations Subcommittee on National Security, Department of State and Related Programs.
AROUND THE AGENCIES
SOMETHING TO TALC ABOUT — A panel of scientists told FDA Commissioner Marty Makary on Tuesday that there's broad consensus that talc is likely carcinogenic in some forms and increases inflammation — properties that could justify attempts to remove the additive from the food and drug supply, Lauren reports.
The expert roundtable at FDA headquarters acknowledged there are still scientific unknowns about the risks of ingesting talc, which is used in some pharmaceuticals as a filler and in some candies and gums. But they said enough safety concerns exist — as do safer alternatives for drugmakers — that warrant a shift away from its use.
While Makary acknowledged the lack of data on whether talc is implicated in several chronic diseases affecting the gut, he said enough evidence suggests the issue 'deserves a hard look by the FDA.'
'I'm not suggesting that talc is the driver of our chronic disease epidemic,' he said. 'But if we generally believe it's pro-inflammatory and kids are ingesting it, aside from the potential cancer-causing effects, shouldn't there be reason for concern?'
What's next: It's unclear whether and how the discussion might inform FDA action.
'Any future regulatory decisions will be made only after further scientific analysis and careful consideration of all available evidence,' HHS spokesperson Andrew Nixon said.
MAHA LEADERS TO KENNEDY: STAND FIRM — Make America Healthy Again leaders are pushing back against the pesticides industry and members of Congress concerned that an upcoming White House report will target the chemicals used by farmers.
A letter to Kennedy today from MAHA leaders, including former Kennedy campaign finance director Dave Murphy and Zen Honeycutt, executive director of Moms Across America, urges Kennedy to 'stand firm' against a farmer-led petition and a letter from 79 Republican members of Congress that ask the secretary not to discredit safety-tested pesticides in a MAHA Commission review to be released this week.
The pushback comes after Sen. Cindy Hyde-Smith (R-Miss.) warned Kennedy during a Senate Appropriations Committee on Tuesday that the report better not target the chemicals without definitive proof they cause disease.
'It's going to be a shame if the MAHA Commission issues a report suggesting, without substantial facts and evidence, that our government got things terribly wrong when it reviewed a number of crop-protection tools and deemed them to be safe,' Hyde-Smith told Kennedy, referencing the Make America Healthy Again panel he leads.
Kennedy denied that the report would target American farmers. 'The report will not put a single farmer in this country out of business,' he said, adding: 'We are not going to do anything to jeopardize that business model.'
Names in the News
James Swann is now director of communications at America's Essential Hospitals. He previously was director of communications and public affairs at AHIP.
WHAT WE'RE READING
The New York Times reports on a new system to evaluate traumatic brain injuries.
POLITICO's David Lim reports on new details on the Trump administration's most favored nations policy.
The Associated Press reports on how blood and urine biomarkers can reveal how much ultraprocessed foods we eat.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
an hour ago
Trump says Epstein 'stole' young women from Mar-a-Lago spa, including Virginia Giuffre
WASHINGTON -- President Donald Trump said Tuesday that Jeffrey Epstein 'stole' young women who worked for the spa at Mar-a-Lago, the latest evolution in his description of how their highly scrutinized relationship ended years ago. One of the women, he acknowledged, was Virginia Giuffre, who was among Epstein's most well-known sex trafficking accusers. Trump's comments expanded on remarks he had made a day earlier, when he said he had banned Epstein from his private club in Florida two decades ago because his one-time friend 'stole people that worked for me.' At the time, he did not make clear who those workers were. The Republican president has faced an outcry over his administration's refusal to release more records about Epstein after promises of transparency, a rare example of strain within Trump's tightly controlled political coalition. Trump has attempted to tamp down questions about the case, expressing annoyance that people are still talking about it six years after Epstein died by suicide while awaiting trial, even though some of his own allies have promoted conspiracy theories about it. Ghislaine Maxwell, Epstein's imprisoned former girlfriend, was recently interviewed inside a Florida courthouse by the Justice Department's No. 2 official, Deputy Attorney General Todd Blanche, though officials have not publicly disclosed what she said. Her lawyers said Tuesday that she's willing to answer more questions from Congress if she is granted immunity from future prosecution for her testimony and if lawmakers agree to satisfy other conditions. Aboard Air Force One while returning from Scotland, Trump said he was upset that Epstein was 'taking people who worked for me.' The women, he said, were 'taken out of the spa, hired by him — in other words, gone.' 'I said, listen, we don't want you taking our people,' Trump said. When it happened again, Trump said he banned Epstein from Mar-a-Lago. Asked if Giuffre was one of the employees poached by Epstein, he demurred but then said 'he stole her.' The White House originally said Trump banned Epstein from Mar-a-Lago because he was acting like a 'creep.' Giuffre died by suicide earlier this year. She claimed that Maxwell spotted her working as a spa attendant at Mar-a-Lago in 2000, when she was a teenager, and hired her as Epstein's masseuse, which led to sexual abuse. Although Giuffre's allegations did not become part of criminal prosecutions against Epstein, she is central to conspiracy theories about the case. She accused Epstein of pressuring her into having sex with powerful men. Maxwell, who has denied Giuffre's allegations, is serving a 20-year-prison sentence in a Florida federal prison for conspiring with Epstein to sexually abuse underage girls. A spokeswoman for the House Oversight Committee, which requested the interview with Maxwell, said the panel would not consider granting the immunity she requested. The potential interview is part of a frenzied, renewed interest in the Epstein saga following the Justice Department's statement earlier this month that it would not be releasing any additional records from the investigation, an abrupt announcement that stunned online sleuths, conspiracy theorists and elements of Trump's political base who had been hoping to find proof of a government coverup. Since then, the Trump administration has sought to present itself as promoting transparency, with the department urging courts to unseal grand jury transcripts from the sex-trafficking investigations. A judge in Florida last week rejected the request, though similar requests are pending in New York. In a letter Tuesday, Maxwell's attorneys said that though their initial instinct was for Maxwell to invoke her Fifth Amendment right against self-incrimination, they are open to having her cooperate provided that lawmakers satisfy their request for immunity and other conditions. But the Oversight Committee seemed to reject that offer outright. 'The Oversight Committee will respond to Ms. Maxwell's attorney soon, but it will not consider granting congressional immunity for her testimony," a spokesperson said. Separately, Maxwell's attorneys have urged the Supreme Court to review her conviction, saying she did not receive a fair trial. They also say that one way she would testify 'openly and honestly, in public,' is in the event of a pardon by Trump, who has told reporters that such a move is within his rights but that he has not been not asked to do it. 'She welcomes the opportunity to share the truth and to dispel the many misconceptions and misstatements that have plagued this case from the beginning,' the lawyers said.
Business Wire
an hour ago
- Business Wire
Veolia Heads a Groundbreaking Wastewater Epidemiological Surveillance Across Europe
PARIS--(BUSINESS WIRE)--Regulatory News: Veolia (PARIS:VIE), the world leader in water technologies, is at the helm of a groundbreaking European epidemiological surveillance program that leverages wastewater as a real-time health indicator. The goal: detect emerging threats early and protect urban populations across the continent. Veolia will oversee the monitoring aspect of this three-year program and will analyze up to 500 wastewater samples collected from European cities in its laboratories in Spain. Each sample will undergo more than 500 in-depth analyses, targeting a wide range of pollutants, viruses, bacteria, and drug residues. This initiative is aligned with the revised European directive on wastewater treatment, which formally embeds epidemiological surveillance as a pillar of public health. It is also part of the European 'One Health' strategy, which will enable the analysis of collective behavior, the assessment of the impact of public policies, and the identification of new threats, while strengthening Europe's health sovereignty. This principle was recently reiterated in the European Strategy for Water Resilience. Estelle Brachlianoff, CEO of Veolia said: 'Being a pioneer means anticipating tomorrow's challenges, and that's exactly what we're doing here, by transforming wastewater into an early warning tool on a European scale. This project is a concrete embodiment of our GreenUp strategic plan: our environmental solutions are also solutions for the health of citizens and the resilience of European territories. We are delighted to be able to bring the Group's expertise in water treatment and environmental health to the European Union, and to pave the way for a more connected, intelligent, and preventive public health system.' The project is led by Veolia, in partnership with the CSIC (Spanish National Research Council), Cetaqua (Veolia Water Technology Center), and the University of Santiago de Compostela. It is based on more than ten years of field experience in wastewater monitoring in Madrid, Barcelona, and Seville, covering nearly a third of the Spanish population. Daniel Tugues, CEO of Veolia Spain, said: 'The Covid-19 pandemic has revealed the untapped potential of wastewater for public health monitoring. This project puts that learning into practice on a large scale. We are very proud that the expertise of our teams is recognized at the European level. Thanks to this project, Spain is at the forefront of a new approach to environmental health, combining scientific rigor, technological innovation, and a commitment to the common good.' ABOUT VEOLIA Veolia group aims to become the benchmark company for ecological transformation. Present on five continents with 215,000 employees, the Group designs and deploys useful, practical solutions for the management of water, waste and energy that are contributing to a radical turnaround of the current situation. Through its three complementary activities, Veolia helps to develop access to resources, to preserve available resources and to renew them. In 2024, the Veolia group provided 111 million inhabitants with drinking water and 98 million with sanitation, produced 42 million megawatt hours of energy and treated 65 million tonnes of waste. Veolia Environnement (Paris Euronext: VIE) achieved consolidated revenue of 44.7 billion euros in 2024.
Medscape
an hour ago
- Medscape
FDA Puts Alopecia Treatment on Fast Track
The FDA has granted a 'Fast Track' designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe alopecia areata, according to a press release from the manufacturer, Nektar Therapeutics. The indication applies to adults and children aged 12 years or older weighing at least 40 kg. REZPEG is a novel biologic that targets 'the interleukin-2 receptor complex in the body to stimulate proliferation of inhibitory immune cells known as regulatory T cells,' according to the company. The Fast Track designation was created to help bring important new treatments to patients as soon as possible and is granted to investigational therapies that may address unmet medical needs for serious conditions, according to the press release. REZPEG is being evaluated in the ongoing Rezolve AA phase 2b study in patients with alopecia areata. In the study, 90 patients with severe-to-very severe alopecia areata (defined as scalp involvement of 50% or more) who were not previously treated with a JAK inhibitor or another biologic were randomized to two different doses of REZPEG or placebo. It will be a self-administered injection, the company said. The primary efficacy endpoint is the mean percent change in the Severity of Alopecia Tool (SALT) score at the end of the 36-week induction period, according to the company. Secondary endpoints include the proportion of participants with reductions in SALT scores of 50% or more at 36 weeks and other timepoints, as well as the mean percent improvement in SALT score at multiple timepoints and the proportion of patients achieving an absolute SALT score ≤ 20. Data from the trial are scheduled to be reported in December 2025, according to the company. The designation follows a previous Fast Track designation for the product as a treatment for moderate-to-severe atopic dermatitis in February.
